Can memantine prevent memory impairment induced by MDMA in humans

Randomised, double‑blind, placebo‑controlled, four‑way crossover in recreational MDMA users (n=21). Subjects were pretreated with memantine or placebo and, two hours later, received MDMA or placebo, with a washout of at least two weeks between sessions.

Primary outcome was performance on memory tasks; secondary outcomes included event‑related potentials and speech recordings. Screening included ECG, urine and blood tests; each test day lasted approximately six hours.